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Abstract Bovine viral diarrhea virus (BVDV) infections cause respiratory, reproductive,
and enteric disease in cattle. Vaccination raises herd resistance and limits the spread of
BVDV among cattle. Both killed and modified live vaccines against BVDV are available.
While modified live vaccines elicit an immune response with a broader range and a longer
duration of immunity, killed vaccines are considered to be safer. One way to improve the
performance of killed vaccines is to develop new adjuvants. The goal of this research was
evaluate new adjuvants, consisting of combinations of Quil A cholesterol and dimethyldioctadecylammonium (DDA) bromide, for use in killed vaccines. Responses to three novel
killed vaccines, using combinations of Quil A and DDA as adjuvants, were compared to
responses to a commercial modified live and a commercial killed vaccine. Vaccination
response was monitored by measuring viral neutralizing antibodies (VN) levels and by
response to challenge. All three novel vaccines were efficacious based on reduction in virus
isolation, pyrexia, and depression. Compared to a commercial killed vaccine, the three
novel vaccines elicited higher VN levels and reduced injection site inflammation.
Keywords Bovine viral diarrhea virus, adjuvant . Quil A cholesterol .
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Introduction
Reproductive and respiratory disease associated with infection with bovine viral
diarrhea viruses (BVDV) result in significant economic losses for dairy and beef
producers. The term BVDV refers to two distinct groups of viruses, BVDV1 and
BVDV2, which are classified as two different species within the Pestivirus genus of the
Flavivirus family (Ridpath 2008) Acute infections result in disease of varying severity,
depending on the viral strain, the immune and reproductive status of the host, and the
presence of secondary pathogens (Callan and Garry 2002; Evermann and Barrington
2005). Acute infections with BVDV, regardless of clinical presentation, are always
accompanied by immune suppression due, at least in part, to the death of immune cells
within lymph nodes and gut associated lymphoid tissue and reduction of numbers of
circulating white blood cells (Liebler-Tenorio et al. 2002, 2004; Liebler-Tenorio et al.
2003a, b). The suppression of the immune system leaves infected animals vulnerable to
secondary infections. In addition to acute infections, noncytopathic BVDV strains may
establish life-long persistent infections. These persistent infections are the result of fetal
exposure to BVDV before the development of the immune system (Brock et al. 2005).
The PI animal is thought to be the major vector for introduction of BVDV into herds.
There are two different goals for BVDV vaccination, one is to limit clinical disease
(including immunosuppression) and viral shed following acute infections. The other is to
prevent the fetal infection that leads to persistent infection.
Both modified-live virus (MLV) and killed vaccines are available for control of
BVDV infections (Fulton 2005). MLV vaccines elicit a faster, longer lasting and
broader response. However, post-vaccinal disease, particularly mucosal disease in PI
animals, has been observed following vaccination with MLV vaccines. Killed vaccines
are more stable and are safe for use in all animals. Killed vaccines are comprised of
viral antigen (Ag) that has been inactivated by various methods, such as heat, chemicals
or physical disruption, and can no longer replicate in vivo. Most commonly in
inactivated BVDV vaccines, the Ag is enhanced with an adjuvant component, because
the viral Ag is typically poorly immunogenic (Kwissa et al. 2007). Although considered
to be the safer, killed vaccines may have incomplete or short-lived immune responses
compared to MLV vaccines. Booster vaccinations are usually required to achieve
protective immune responses. In addition, use of adjuvant may result in injection site
reactions.
Adjuvant combinations (coadjuvantation) can potentially overcome some of the
problems observed with killed vaccines (Fraser et al. 2007). The Q-series of adjuvants,
used in this study, are comprised of multiple interchangeable molecules, including Quil A,
cholesterol, and dimethyldioctadecylammonium (DDA) bromide. Quil A is an enriched
fraction of a tri-terpenoid saponin derived from the bark of the South American tree
Quillaja saponaria commonly used in veterinary vaccines (Kirk et al. 2004). When Quil A
is combined with cholesterol (QAC) it forms helical, nanometer scale worm-like micelles
(Mitra and Dungan 2001). DDA is a cationic, micelle-forming surfactant (Lincopan et al.
2007). In this study, three experimental vaccines, adjuvanted with Q-series adjuvants were
compared to commercially available vaccines. Vaccination response was determined by
measuring viral neutralizing antibodies (VN) levels before and after vaccination and by
response to exposure to live BVDV following vaccination (challenge). The response to
challenge was monitored by measuring changes in circulating white blood cells, basal
temperature, and virus isolation.
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Materials and methods
Experimental design
Cattle were assigned to one of six vaccination protocols (Table 1). In protocol 1 (control
protocol), cattle were injected subcutaneously, on days 0 and 21, with a sterile saline
solution. In protocol 2 cattle were injected subcutaneously with a modified live virus
vaccine on day 0 of the study (prepared by the protocol used for a commercial vaccine). In
protocol 3 (killed vaccine prepared by protocol used for another commercial vaccine), cattle
were injected subcutaneously on days 0 and 21 of the study. In protocols 4, 5, and 6, cattle
were injected subcutaneously, on days 0 and 21 of the study, with experimental vaccines
that were adjuvanted with different formulations of the Q-series adjuvants (see below).
Screening, housing and allotment of animals
Healthy, non-vaccinated beef calves (of mixed breed and gender), approximately 7 to
12 months of age (body weight range 272 to 442 kg) were tested and confirmed negative
for BVDV antigen based on immunohistochemistry performed on skin biopsies (University
of Nebraska Veterinary Diagnostic Center, Lincoln, NE) (Brodersen 2004). Animals were
screened for serum antibodies against BVDV by virus neutralization assay and only animals
with VN titers <1:2 were enrolled in the study (Ridpath et al. 2008).
Processing at arrival included administration of an injectable parasiticide (doramectin,
Pfizer Animal Health, New York, NY) and a metaphylactic anti-microbial for BRD
(tulathromycin, Pfizer Animal Health, New York, NY). Acclimatization began approximately 1 week before Day 0. The animals had ad libitum access to commercial feed and to
water from a municipal source.
This 56-day study used a generalized, randomized, incomplete block study design, with
animals assigned to blocks of five animals each by body weight. The animal was the
experimental unit. Within each block, treatments were randomly assigned to animals using
a computer-generated plan. Animals were housed by vaccination protocol group from Day
0 to Day 21. On Day 35, the calves were randomly assigned to commingled pens and
Table 1 Vaccination protocols for 6 experimental groups
Group

1

2

3

4

5

6

Negative
control

MLV
vaccine

Killed
vaccine

Experimental
vaccine

Experimental
vaccine

Experimental
vaccine

Virus

None

Live virus Killed
virus

Killed virus

Killed virus

Detergent
extracted virus

Adjuvant

None

None

PreZent-A QAC

QAC

QAC

DDA

DDA

DDA

Carbopol

Carbopol

Carbopol

Day 0
Day 21

Day 0
Day 21

R1005
Inoculation Day 0
Day 21
a

High titer extract

b

Low titer extract

Day 0

Day 0
Day 21

Day 0a
Day 21b
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moved into isolation rooms before challenge with BVDV-2 on Day 42. Animals were
housed by block with two blocks in each pen, six pens total. Blocks were randomly
assigned to pens in each phase such that the weight variability within each pen was
minimized. This design was balanced, 10 animals in each treatment group.
Vaccination protocols
Animals in group 1 received 0.9% sodium chloride sterile solution, on days 0 and 21, and
served as the control group. Animals in group 2 received a MLV BVDV-2 vaccine. The
antigen concentration and formulation of this vaccine was the same virus and titer as that
used in the production of the BoviShield Gold® vaccine line (Pfizer Animal Health,
Kalamazo, MI). Briefly, this vaccine was a freeze-dried preparation of modified-live
BVDV2 (propagated on an established bovine cell line) and was rehydrated with 0.9%
sodium chloride sterile solution. This vaccine contained no adjuvant and was only
administered once to this group on Day 0. Animals in group 3 received a killed virus
BVDV-2 [inactivated with 5% binary ethyleneimine (BEI); 44–72 h inactivation at 34–38°
C] vaccine adjuvanted with Amphigen and QAC. This adjuvant is the same as the adjuvant
in CattleMaster® Gold™, (PreZent-A™, Pfizer Animal Health). The BVDV2 antigen
concentration and formulation of this vaccine was also the same as that of the CattleMaster
Gold vaccine line (Pfizer Animal Health). Animals in groups 4, 5, and 6 received killedvirus vaccines containing novel adjuvants as listed in Table 1. The concentration of BVDV
Ag in the vaccines used for groups 4 and 5 was the same as the concentration present in the
killed vaccine used for group 3 (2,750 RU/mL). The animals in group 6 received an
experimental vaccine that differed in the method of antigen preparation but had the same
adjuvant as the vaccine used for group 4. A detergent extraction method was used to
prepare Ag enriched for BVDV proteins. The BVDV2 virus was extracted with sodium
deoxycholate (1.5 h with mixing, 25°C), clarified by centrifugation (3,000×g for 30 min at
25°C), concentrated by dialysis using a 10 kD-cutoff ultrafiltration membrane, and
sterilized using a 0.2-micron filter. Two different antigen concentrations were used in the
two doses. The Ag concentration in the vaccine used for the first vaccine dose in group 6
was at a higher concentration (>12,000 RU/mL). The concentration in the second dose was
2,750 RU/mL.
All treatments were administered subcutaneously in a single 2-mL dose on Days 0 and
21, with the exception of Group 2 as noted above.
Formulation of vaccines
The following stock solutions were used in the formulation of the adjuvants used for
protocols 4, 5, and 6. Quil A was dissolved in water to prepare a 50 mg/mL stock solution.
Cholesterol (FabriChem Inc., Trumball, CT) was dissolved in ethanol to make a 17 mg/mL
stock solution and the DDA was dissolved in ethanol to make an 18 mg/mL stock solution.
Both of these stocks were filter sterilized using a 0.2-μ filter. Carbopol 974 P NF, a
synthetic anionic polymer used as an adjuvant in commercial vaccines, was dissolved in
water to prepare a 1.5% (w/v) stock solution and sterilized by autoclaving at 121°C for
20 min. The stock for Bay-R1005 was dissolved in phosphate buffer at a stock solution of
4.57 mg/mL and filter sterilized using a 0.2-μ filter. Bay-R1005 [N-(2-Deoxy-2-Lleucyclamino-b-D-glucopyranosyl)-N-octadecylodecanoylamide hydroacetate] is an amphiphilic molecule that forms micelle in aqueous solution. It is a common adjuvant component
in commercial vaccines.
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The adjuvant used for protocols 4 and 6 was identical. These protocols differed only in
the viral antigen. The Group 4 and 6 formulations contained buffer, 50-μg/mL Quil A, 50μg/mL cholesterol, 25-μg/mL DDA, and 0.075% w/v of Carbopol. Antigen was combined
with (add 80% v/v) buffer followed by addition of Quil A, cholesterol-ethanol, and DDAethanol using constant stirring. An appropriate volume of Carbopol was added to attain a
final concentration of 0.075%. The pH was adjusted to pH 7±0.2 with 4N NaOH. The viral
antigen for protocols 4 and 5 were identical. The adjuvant for protocol 5 differed from that
of protocols 4 and 6 in that R1005 also was added to a final concentration of 50 μg/mL for
this formulation and the pH was not adjusted.
Antigen concentrations in vaccines were determined by ELISA. Readings were
compared to a standard curve, which was prepared using an USDA accepted manufacturing
reference standard. Antigen concentrations are stated in relative units (RU). The virus strain
used in all vaccines was strain 53637. This strain belongs to the BVDV2a subgenotype.
BVDV-2 challenge
On Day 42 all the animals were challenged with a noncytopathic BVDV-2a (strain 24515)
at a concentration 5.4 log10 TCID50 per 5-mL dose. The challenge inoculum was delivered
intranasally, approximately 2.5 mL per nostril, using a compressed gas nebulizer. Dose
titration assays were conducted on pre- and post-challenge samples as described previously.
(Cortese et al. 1998)
Please note that two different BVDV2a strains were used in vaccine formulations (strain
53637) and challenge studies (strain 224515). Based on phylogenetic analysis performed
using sequences from the 5′ untranslated region, these two strains belong to the same
subgenotype, but are not identical.
Blood testing
Blood samples were collected on days 0, 21, 41, and 56. Serum from blood samples was
harvested, divided into aliquots, and submitted for testing or stored frozen at <−20°C. Viral
neutralizing titers in collected sera were determined against three BVDV1a strains (BVDV1aSinger, BVDV1a-5960, and BVDV1a-NADL), three BVDV1b strains (BVDV1b-TGAC,
BVDV1b-Illc, and BVDV1b-2110), and three BVDV2a strains (BVDV2a-296c, BVDV2a-ND
8799, and BVDV2a-MsSt T-4529) as described previously (Ridpath et al. 2010). Buffy coat
samples were harvested from whole blood collected on days 40 through 56. These samples
were assayed for replicating BVDV by tissue culture isolation followed by Ab staining
(Cortese et al. 1998). Total circulating white blood cell counts (WBC) and platelet counts were
determined as described previously (Ridpath et al. 2007).
Health observations
On Days -1 to 39, animals were observed daily for general health. After the BVDV-2
challenge, the animals were monitored each morning for clinical signs of BVDV disease
(depression, nasal discharge, and respiratory distress) and each afternoon for general health.
For 1 h after each vaccination animals were observed for systemic reactions, such as
anaphylaxis, depression, reduced coordination, increased respiration, diarrhea, inappetence,
or trembling. Injection-site reactions were observed on Days 0, 1, 2, 3, 7, and 21 for the
first vaccination, and on Days 21, 22, 23, 24, 28, and 42 for the second vaccination. All
palpable injection-site reactions were measured (length × depth × width) and the size
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recorded. Rectal temperatures were recorded from day -1 to day 56. Fever was defined as a
rectal temperature >40.3°C (104.5°F). Leukopenia was defined as a 40% decrease in WBC
counts compared to pre-challenge WBC count means.
Data summary and analyses
In the challenge phase, rectal temperatures, serology data, viremia data, WBC counts, and
platelet counts were analyzed with a general linear repeated measures mixed model with
fixed effects (treatment, time-point, and treatment by time-point interaction) and random
effects (pen, animal within treatment and pen, which was the animal term, and the residual).
Linear combinations of the parameter estimates were used in a priori contrasts after testing
for a significant (P≤0.05) treatment or treatment by time-point effect. Comparisons were
made between treatments at each time-point. Back transformed least squares means (from
serology), their standard errors and their 90% confidence intervals were calculated from
least squares parameter estimates obtained from the analyses.

Results
Serum neutralizing titers prior to challenge
All animals were seronegative to BVDV-1 and BVDV 2 before vaccination (Day -1).
Figure 1 presents SN titers on Day 41 (41 days past first vaccination, 20 days after the
second vaccination, and 1 day before challenge). On day 41, group 1 (control animals) were
seronegative to BVDV-1 and BVDV-2. All animals in Groups 3 through 6, and eight of 10
animals in Group 2, had BVDV-2 titers of at least 1:8 on Day 41. The mean BVDV-1 and

Fig. 1 Average neutralizing titers of animals from different treatment groups against strains of BVDV1a,
BVDV1b, and BVDV2
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BVDV-2 titers of Group 2 was statistically significantly (P≤0.0015) smaller than those of
Groups 3, 4, 5, and 6. The mean BVDV-2 titer of Group 6 was statistically significantly
(P≤0.0335) smaller than those of Groups 3, 4, and 5. The mean BVDV-1 titer of Group 4
was statistically significantly (P≤0.0357) smaller than the mean of Group 3.
Response to challenge
Virus isolation was performed on samples collected between Days 41 and 56 (Table 2).
Virus positive samples were detected longer and more frequently from animals in group 1
than animals from groups 2 through 6. A statistically significant difference (P≤0.0031) was
found between the number of positive animals in Group 1 (10 of 10) compared to the
numbers of positive animals (one of 10 to three of 10) for all other treatment groups.
Results for Groups 2 through 6 did not differ significantly from each other.
Figure 2 graphs rectal temperatures throughout the study. Slight increases in mean rectal
temperatures of generally <0.56°C (1°F) from pre-vaccination levels were observed following
the primary and booster vaccinations in all treatment groups. Following challenge, the mean
rectal temperature of Group 1 first rose to >39.4°C (103.0°F) on Day 50 and peaked on Day
52 at 40.1°C (104.2°F). The mean rectal temperatures for Groups 2, 3, and 5 never exceeded
39.4°C (102.9°F) on any day. For Group 4, a mean temperature greater than 39.4°C (103.0°
F) was only recorded on 1 day (day 51). The mean temperature for Group 6 peaked at 39.6°C
(103.3°F) on Day 52. Using the pre-determined, post-challenge fever criterion listed in 9 CFR
§113.215, eight of 10 animals in Group 1, no animals in Groups 2 and 3, one of 10 animals in
Groups 4 and 5, and two of 10 animals in Group 6 were febrile. The number of febrile
animals in Group 1 was statistically significantly larger (P≤0.0190) than those of all other
groups. The differences observed between mean daily temperatures for groups 2 through 6
were not statistically significant.
Figure 3 plots the number of animals with leukopenia by study day. For Group 1, there
was at least one animal with leukopenia (> 40% decrease in WBC from baseline) every day
from Days 46 through 56. In contrast, there were never any leukopenic animals in Group 2.
For Groups 3, 4, 5, and 6, leukopenic animals were present on Days 47 through 50, 47
through 49, 47 through 50, and 47 through 51, respectively. All animals in Group 1, eight
of 10 in Group 6, one of 10 in Group 3, and three of 10 in both Groups 4 and 5 experienced
leukopenia, none (0 of 10) of the animals in Group 2 were leukopenic. There were no
significant differences (P>0.05) in platelet counts among any of the treatment groups on
any study day.

Table 2 Results of virus isolation
Group # of animals with at
least 1 VI pos
sample

# of days VI pos
samples detected in
group

Greatest # of animals VI
pos on any one sampling
date

Day of first
VI pos
sample

Day of
last VI
pos

1

10

11

10

46

56

2

3

4

1

47

51

3

1

2

1

47

48

4

2

3

1

47

50

5

2

2

1

47

49

6

2

4

2

49

52
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Fig. 2 Average daily temperature of animals from each treatment group

There were no statistically significant differences (P>0.05) among groups in the
occurrence of depression, nasal discharge, or increased respiratory effort. One animal in
Group 4 was removed from the study on Day 53 due to a severely swollen left shoulder that
became infected. The injury was not related to vaccination.
Injection-site reactions
The number of animals with observable infection site reactions and the size of the largest
reaction are detailed in Table 3. The largest reactions occurred in Group 3 on the days
following vaccinations, with reaction sites measuring from 0 to 133.52 mL on Day 1 and 0
to 27.44 mL on Day 22. Small residual reactions were still palpable in Groups 1, 2, 3, and 6
on Day 42. Reactions in all groups resolved rapidly within 48 h of vaccination. The
volumes of reactions for Group 3 were statistically significantly (P≤0.0497) larger than
those of Group 1 on Days 22, 23, and 24, and Group 2 on Days 22 through 24 and 28, and
larger than those of Groups 4, 5, and 6 on Days 22 through 24.

Discussion
Serological response as determined by development of neutralizing antibodies and clinical
presentation following challenge exposure are the most commonly used methods to gauge
the protective response induced by BVDV vaccines (Kelling 2004). In this study, two doses
of any of the killed vaccines resulted in higher neutralizing titers than one dose of the MLV
vaccine. The highest titers were observed after use of the conventional (prepared according
to protocol used for a commercially available vaccine) killed vaccine. Titers in all animals
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Fig. 3 Number of leukopenic animals from each treatment group following challenge on day 42

were higher against BVDV2 strains compared to BVDV1a or BVDV1b strains reflecting
the inclusion of BVDV2, but not BVDV1a or BVDV1b, antigen in the vaccines.
Animal receiving mock vaccinations did not develop measurable titers of neutralizing
antibodies prior to challenge and were not protected from viral replication or clinical
disease following challenge exposure as determined by virus isolation, pyrexia, and
leukopenia. Virus was isolated from at least one animal in all vaccinated groups but less
frequently than from animals in the non-vaccinated group and for a shorter duration of time.
Among the vaccinated groups, virus was isolated from more animals in Group 2 (MLV
vaccine, 3 animals) compared to Groups 3, 4, 5, and 6 (killed virus vaccines, 1–2 animals).
However, there was no significant difference in the length of viral shed between animals
vaccinated with MLV vaccine and animals vaccinated with killed vaccines.
More animals, vaccinated with the three experimental killed vaccines, experienced
pyrexia compared to animals vaccinated with the conventional killed and MLV vaccines.
However, only 1–2 animals were affected and the pyrexia was low grade and of short
duration compared to non-vaccinated animals. Similarly more animals, vaccinated with the
three experimental killed vaccines, experienced leukopenia compared to the animals
vaccinated with the conventional killed and MLV vaccines. The number of leukopenic
animals was significantly higher in group 6 compared to the other vaccinated groups and
was only slightly lower than the non-vaccinated group. The duration of leukopenia was
similar in groups 3, 4, 5, and 6 (both conventional and experimental killed vaccines) and
was significantly shorter than the duration of leukopenia in the non-vaccinated group.
Injection site reactions were more pronounced in animals vaccinated with the
conventional killed vaccine. The function of adjuvants is to augment the effects of a
vaccine by stimulating the immune system to respond more strongly to the vaccine antigen.
While the exact mode of action of most adjuvants is unknown it is thought that they work
by mimicking specific sets of evolutionarily conserved pathogen-associated molecular
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3

7

21
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28

42

a

Volume in mL

3

0/10

Total measureable
observations
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1.31

2
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0/10
1/10
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0/10

0/10

0/10
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1.18

#
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Animals reactiona

#
Largest
Animals reactiona

2

Group 2

Group 1

1

Days post 1st
vaccination

Table 3 Injection site reactions

44
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4/10
4/10

5/10

8/10

1/10

6/10

4/10

9/10

1/10

1.57

4.19
23.04

9.42

37.44

0.26

3.53

5.24

15.71

133.52

#
Largest
Animals reactiona

Group 3

17

1/10

0/10
5/10

2/10

2/10

1/10

2/10

1/10

1/10

2/10

.09

4.91

2.75

2.95

0.03

2.45

1.57

2.62

4.12

#
Largest
Animals reactiona

Group 4

11
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4/10

1/10

3/10
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0/10
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17.02
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#
Largest
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Group 5
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5.04

4.58

39.27
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Group 6
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patterns (PAMPs). The immune system recognizes PAMPs as non self molecules and
activates the innate immune system. Activation of the innate immune system by adjuvants
results in a greater immune response. However, over stimulation or stimulation that elicits
an inappropriate response results in adverse reactions that expend physiological resources
but do not contribute to enhanced protection. An example of an inappropriate response is
injection site reactions. Swelling at the injection site increases animal discomfort and may
reduce carcass quality. These reactions result from a nonspecific irritation of the immune
system and do not contribute to improved protection against specific vaccine antigen. The
perfect adjuvant would increase the strength of the vaccine antigen specific response (as
reflected by development of neutralizing antibodies) and have very limited nonspecific
immune irritation response (as reflected by little or no injection site reactions).
While eliciting the lowest titers of serum neutralizing antibodies, the MLV vaccine
exhibited the highest level of protection based on prevention of pyrexia and leukopenia.
Higher protection in spite of lower levels of neutralizing antibodies may be related to the
stimulation of T cell responses in addition to B cell responses. It is interesting to note that
while preventing clinical presentation of disease, the MLV vaccine was no more effective
than killed vaccines in preventing viremia. The experimental vaccine used in Group 6,
while giving some protection, was the least effective of the vaccines. This suggests that the
process used for enriching for viral proteins, may have eliminated or reduced antigens that
are important to the development of protective immunity.
Protection elicited by the experimental killed vaccines used in groups 4 and 5 was
similar or only slightly reduced from that of the conventional killed vaccine. These two
experimental vaccines demonstrated an advantage over the conventional killed vaccine in
that they had significantly reduced injection site reactions. This suggests that these
adjuvants maintained the protective immune response while ameliorating non-protective
inflammatory responses. Vaccination always carries with it a physiological cost. Production
of an immune response requires energy and can result in animal discomfort. It is desirable
to produce the greatest protective response at the lowest physiological expense. One way to
decrease the physiological cost is to reduce non-protective responses. Non-protective
inflammatory responses in particular contribute to physiological cost, increase animal
discomfort and may decrease carcass value. The advantage of these vaccines would lie in
their ability to produce a protective immune response as a reduced physiological cost.
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